Novan Inc
F:6LUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Haitong Unitrust International Financial Leasing Co Ltd
HKEX:1905
|
CN |
|
M
|
Maman Cargo Terminals & Handling Ltd
TASE:MMAN
|
IL |
|
B
|
Bright Packaging Industry Berhad
KLSE:MBRIGHT
|
MY |
|
Sentage Holdings Inc
NASDAQ:SNTG
|
CN |
|
Copa Holdings SA
NYSE:CPA
|
PA |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its Industry Average (13.5), the stock would be worth €-338 (33 800 525% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0 | €0 |
0%
|
| Industry Average | 13.5 | €-338 |
-33 800 525%
|
| Country Average | 13.3 | €-333.46 |
-33 345 650%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Novan Inc
F:6LUA
|
1.3k EUR | -0 | -0 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883.9B USD | 52.6 | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.2B USD | 23.9 | 21.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.5B GBP | 21.9 | 31.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.4 | 19.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
299.1B USD | 18.2 | 16.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.4B CHF | 15.9 | 21.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 880.9 | -81.1 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8.9 | 10.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161B USD | 13.8 | 20.7 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120B USD | 8.5 | 17 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8.8 |
| Median | 13.3 |
| 70th Percentile | 20.1 |
| Max | 3 188 432.5 |
Other Multiples
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
